The Relative Strength (RS) Rating for Vir Biotechnology headed into a higher percentile Friday, as it got a lift from 65 to 71.
This exclusive rating from Investor's Business Daily identifies share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Vir Biotechnology can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Vir Biotechnology is not currently near a potential buying area. See if the stock goes on to form a sound pattern that could launch a new move.
Vir Biotechnology reported 0% EPS growth in its most recent report. Sales increased -10%. The next quarterly results are expected on or around Feb. 20.
The company holds the No. 249 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, Catalyst Pharmaceuticals and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
